VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
REGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
REGNRegeneron Pharmaceuticals, Inc.
$957.76$98.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksREGNCash Flow

Regeneron Pharmaceuticals, Inc. (REGN) Cash Flow Statement

30Y historyFree accessUpdated daily

Free cash flow of $1.5B in 2026Q3 implied a 29.0% margin, but quarterly conversion swung from 0.25 to 1.48 times net income and buybacks of $399.7M to $1.2B per quarter often consumed most of the cash generated, leaving capital returns dependent on timing.

Income StatementBalance SheetCash FlowRatios

REGN Cash Flow Statement

Annual statement

REGN Cash Flow Statement

Regeneron Pharmaceuticals, Inc. (REGN) cash flow statement — 30-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations4.61B4.98B4.42B4.59B5.01B7.08B2.62B2.43B2.2B1.31B1.49B1.33B752.43M588.6M-74.61M-141.68M96.34M-72.23M-89.09M27.37M23.07M-30.3M-16.91M-6.13M-110.52M-57.32M-27.91M-13.8M-10.2M-6.1M-20.3M
Operating CF Margin %-34.71%31.13%35.02%41.2%44.06%30.81%37.06%32.71%22.26%30.57%32.43%26.69%27.97%-5.41%-31.78%20.99%-19.04%-37.36%21.89%36.37%-45.77%-9.72%-10.67%-502.65%-260.87%-47.08%-40%-26.7%-18.43%-84.23%
Operating CF Growth %-43.68%12.63%-3.78%-8.39%-29.18%170.47%7.74%10.7%67.94%-12.03%11.66%76.86%27.84%888.84%47.34%-247.06%233.38%18.92%-425.46%18.62%176.17%-79.17%-175.71%94.45%-92.82%-105.37%-102.25%-35.29%-67.21%69.95%-11.54%
Net Income4.82B4.5B4.41B3.95B4.34B8.08B3.51B2.12B2.44B1.2B895.52M636.06M348.07M424.36M750.27M-221.76M-104.47M-67.83M-82.71M-105.6M-102.34M-95.45M41.7M-107.46M-124.38M-76.18M-23.21M-23.1M-8.6M-11.6M-32.4M
Depreciation & Amortization512.9M543.7M482.9M421M341.4M286.2M235.9M210.3M148.2M145.47M104.75M74.91M52.69M41.2M36.94M31.08M19.69M14.25M11.29M11.49M14.59M15.5M15.36M12.94M8.45M6.08M4.42M3.4M3M4.4M6.1M
Stock-Based Compensation1.01B993.7M982.8M885M725M601.7M432M464.3M427.4M507.28M559.88M459.05M307.24M198.4M94.16M56.09M39.9M31.26M32.52M28.07M00000000000
Deferred Taxes-705.2M-785.4M-757.3M-837.8M-746.4M-147.1M75.6M-130.6M-140M318.81M-360.08M-121.62M-66.6M63.6M-340.16M00-56K0000000000000
Other Non-Cash Items-399.9M-810.6M-82.2M266.3M599.8M181.7M-135M-29.3M12.1M63.57M57.64M52.56M19.63M45.34M56.97M10.37M293K-382K2.25M5.94M17.86M21.86M-15.23M4.06M1.82M1.77M6.14M4.7M2.8M3.7M14.5M
Working Capital Changes-623.2M532.6M-618.3M-94.1M-243.3M-1.92B-1.5B-200.5M-697M-926.53M228.19M229.83M20.24M-190.67M-672.8M-17.46M140.94M-49.47M-52.43M87.47M92.96M27.79M-58.74M84.33M3.58M11.02M-15.25M1.2M-7.4M-2.6M-8.5M
Change in Receivables-1.9B498.1M-554M-338.8M707.8M-1.93B-1.36B-473.1M-268.9M-362.72M-143.83M-491.42M-62.43M-198.66M-590.09M-21.12M-27.54M-30.36M-16.89M000000000000
Change in Inventory112.8M-275.3M-619.7M-271.7M-696.5M-494.3M-529.4M-335.5M-387.9M-314.19M-149.78M-111.83M-60.9M-47.96M-52.62M00-4.57M003.59M1.25M6.91M-1.05M-1.73M-941K4.05M-4M000
Change in Payables1.36B736.8M735.1M598.6M-138.4M866.1M118.9M444.5M210M-23.19M253.98M303.66M162.24M136.68M10.98M0012.96M0000000000000
Cash from Investing-589.4M-629.1M-2.47B-3.19B-3.78B-5.38B-70.6M-2.03B-1.46B-1.01B-1.05B-907.6M-420.78M-355.45M-81.07M128.47M-434.15M146K30.82M-85.72M-155.1M115.49M-4.58M-63.84M-58.52M-75.39M-57.68M17.5M2.4M-38.9M-44.3M
Capital Expenditures-1.06B-1.21B-755.9M-926.4M-590.1M-551.9M-614.6M-429.6M-383.1M-272.6M-511.9M-677.93M-333.01M-156.32M-49.34M-57.22M-99.69M-97.32M-34.86M-18.45M-2.81M-4.96M-6.17M-29.66M-34.37M-8.22M-6.5M-5.7M-3M-2.1M-8.6M
CapEx % of Revenue6.28%8.46%5.32%7.06%4.85%3.43%7.23%6.55%5.71%4.64%10.53%16.52%11.81%7.43%3.58%12.83%21.72%25.66%14.62%14.75%4.43%7.5%3.55%51.58%156.31%37.42%10.96%16.52%7.85%6.34%35.68%
Acquisitions-300K-3.3M-16.5M-54.9M-230.3M551.9M614.6M429.6M1.07B0000000000000000000000
Investments-------------------------------
Other Investing-156.2M0-105.6M0-1.03B-551.9M-614.6M-429.6M-1.08B-26K-41K000-552K-277K1.12M50K-50K0-1.6M000000100K-100K-100K0
Cash from Financing-4.22B-3.72B-2.2B-1.79B-1.01B-1.01B-1.97B-252.1M-77.1M-24.4M-700.39M-262.8M-218.55M72.19M-97.65M384.25M243.31M31.36M-192.86M319.4M185.4M4.08M4.44M108.18M1.72M349.12M92.87M300K-1.4M39.4M66.3M
Debt Issued (Net)0000001.98B0037.1M-40.6M-140.45M-221.73M-2.02M-2.2M389.44M46.52M22.77M-200.81M0003.83M13.51M-426K190.6M-1.5M-1.1M-1.9M-3.9M-3.7M
Equity Issued (Net)-2.02B-3.33B-2.17B-1.09B-563.3M26.9M-6.53B-64.1M110.1M-61.5M-143.2M45.82M-141.54M57.39M-99.75M18.51M196.79M8.6M7.95M319.4M185.01M4.08M614K94.68M2.15M158.52M94.36M1.4M500K43.4M70M
Dividends Paid-383M-370.3M00000000000000000000000000000
Share Repurchases-3.04B-3.97B-3.63B-2.23B-2.53B-2.68B-6.53B-463.9M-191.6M-301.7M-143.2M-160.54M-267.58M-195.09M-163.3M-25.08M-3.8M00000-888K00000000
Other Financing-1.82B-10.3M-33.4M-700.6M-445.7M-1.03B2.58B-188M-187.2M0-516.59M-168.17M144.73M16.82M4.31M-23.7M0000390K00000000-100K0
Net Change in Cash-200.2M634.7M-248.8M-381.6M221.3M690.8M577M150.1M655M277.53M-273.9M160.38M113.11M305.33M-253.33M371.04M-94.5M-40.72M-251.13M261.05M53.37M89.28M-17.05M38.21M-167.32M216.41M7.28M3.9M-9.2M-5.6M1.7M
Free Cash Flow3.59B4.08B3.66B3.67B4.42B6.53B2B2B1.81B1.03B974M652.85M419.43M432.27M-123.95M-198.9M-3.35M-169.55M-123.94M8.93M20.26M-35.26M-23.08M-35.79M-144.89M-65.54M-34.41M-19.5M-13.2M-8.2M-28.9M
FCF Margin %21.23%28.45%25.8%27.96%36.35%40.63%23.58%30.51%27%17.62%20.04%15.91%14.88%20.54%-8.99%-44.61%-0.73%-44.7%-51.98%7.14%31.94%-53.27%-13.26%-62.24%-658.96%-298.29%-58.04%-56.52%-34.55%-24.77%-119.92%
FCF Growth %-13.64%11.35%-0.08%-17.11%-32.23%225.9%0.15%10.4%75.16%6.21%49.19%55.65%-2.97%448.74%37.68%-5846.16%98.03%-36.8%-1488.56%-55.95%157.47%-52.75%35.5%75.3%-121.07%-90.5%-76.44%-47.73%-60.98%71.63%-34.42%
FCF per Share33.9837.5731.8432.2638.9958.1917.4117.4615.788.938.375.673.703.88-1.07-2.20-0.04-2.13-1.570.130.35-0.63-0.41-0.71-3.30-1.56-0.98-0.62-0.43-0.28-1.18
FCF Conversion (FCF/Net Income)0.74x1.11x1.00x1.16x1.16x0.88x0.75x1.15x0.90x1.09x1.66x2.09x2.16x1.39x-0.10x0.64x-0.92x1.06x1.08x-0.26x-0.23x0.32x-0.41x0.06x0.89x0.75x1.20x0.60x1.19x0.53x0.63x
Interest Paid0052.6M73.1M53.7M55.8M23.2M25M22.3M18.7M5.5M10.58M20.35M23.2M00009.35M000000000000
Taxes Paid00743M870.3M1.5B1.22B188.1M342.3M205.6M754.8M481.4M276.09M59.85M1.06M00003.08M000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Lumpy cash generation and buybacks

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Cash Conversion Swings With Working Capital

Based on REGN's reported quarterly figures, operating cash flow to net income ranged from 0.25 in 2024Q2 to 1.48 in 2026Q1, indicating conversion quality that depends heavily on working capital timing rather than steady earnings backing.

The ratio exceeded 1.0 in most recent quarters, which suggests reported profits are being backed by cash, but the swings from 0.25 to 1.48 show that quarterly conversion is not reliable on its own. Working capital changes of -$908.5M in 2024Q2 and +$625.0M in 2025Q3 explain much of this volatility, so investors should view single-quarter cash conversion with caution. A multi-quarter view is more informative for judging earnings quality.

Free Cash Flow Margins Remain Erratic

As reported in financial statements, REGN's free cash flow margin moved from 4.0% in 2024Q2 to 37.8% in 2025Q3 before settling near 29.0% in 2026Q3, a range that points to uneven cash generation.

The latest quarter's 29.0% margin is high relative to the 4.0% to 26.3% band seen across most of the prior eight quarters, which may reflect favorable working capital rather than a durable step-up in underlying cash generation. Free cash flow of $1.5B in 2026Q3 compared with $334.3M in 2026Q2 underscores how sensitive the trend is to timing. Sustained margins above 25% would be a more meaningful signal than any single strong quarter.

Light Capital Intensity Relative to Revenue

Based on REGN's reported figures, capital expenditures have run between 4.9% and 11.1% of revenue, which is modest for a biotechnology company with significant manufacturing and research infrastructure.

Capex of roughly $183.6M to $406.8M per quarter implies that the business does not require heavy ongoing reinvestment to sustain operations. Depreciation and amortization near $121M to $145M per quarter sits below capex in most periods, suggesting modest net asset growth. Investors should monitor whether capex rises materially as pipeline and manufacturing commitments scale.

Buybacks Absorb Most Free Cash Flow

According to reported quarterly data, REGN deployed heavy share repurchases of $399.7M to $1.2B per quarter in most periods, which often exceeded or closely tracked free cash flow generation.

Buybacks of $1.2B in 2026Q2 and $1.1B in 2025Q2 compared with free cash flow of $334.3M and $967.6M in those periods, implying that repurchases were funded at or above internally generated cash in some quarters. Dividends were absent in 2024 and only about $93M to $98M per quarter thereafter, so capital return is dominated by buybacks. This pattern suggests management prioritizes share count reduction, and the sustainability of that policy depends on continued cash generation.

Net Income Versus Cash Gap Warrants Monitoring

Based on the supplied quarterly data, cumulative operating cash flow over the ten quarters is broadly comparable to cumulative net income, but the quarterly gap is wide enough to warrant further investigation.

Operating cash flow fell below net income in 2024Q2 ($354.0M against $1.4B) and 2025Q2 ($1.1B against $1.4B), which points to periods where reported earnings were not converting to cash. Stock-based compensation of $220M to $300M per quarter is a non-cash add-back that partly explains the gap but does not account for the full swings. Investors should examine these periods in more detail before treating reported earnings as fully cash-backed.

Cash Strength May Be Overstated by Timing

Based on reported figures, the strongest quarters for free cash flow coincided with favorable working capital swings, which may mean the underlying cash generation is weaker than the headline margin of 29.0% in 2026Q3 suggests.

Working capital inflows of +$625.0M in 2025Q3 and +$468.0M in 2024Q3 align with elevated free cash flow in those quarters, raising the possibility that reported strength reflects timing rather than sustained improvement. Stock-based compensation totaling roughly $1.0B annually is a real economic cost that the operating cash flow figure excludes, which may overstate cash earnings power. Further analysis of receivables and payables trends would help clarify how durable current cash levels are.

REGN — Frequently Asked Questions

Quick answers to the most common questions about buying REGN stock.

How much cash does Regeneron Pharmaceuticals, Inc. (REGN) generate from operations?

Regeneron Pharmaceuticals, Inc. (REGN) generated $4.98B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Regeneron Pharmaceuticals, Inc.'s free cash flow?

Regeneron Pharmaceuticals, Inc. (REGN) generated $4.08B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Regeneron Pharmaceuticals, Inc.'s capital expenditure (CapEx)?

Regeneron Pharmaceuticals, Inc. (REGN) spent $1.21B on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Regeneron Pharmaceuticals, Inc. distribute cash to shareholders?

In 2025, Regeneron Pharmaceuticals, Inc. (REGN) returned $370.3M to shareholders via cash dividends and spent $3.97B on share repurchases. This shows the company's commitment to returning capital to its equity investors.